Today: 21 December 2025
Subscribe
Browse Tag

Bristol-Myers Squibb

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts
16 December 2025
 ·  ·  ·  ·  · 
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a
16 December 2025
 ·  ·  ·  ·  · 
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is ending Monday’s session in the spotlight after a sharp, analyst-driven move that pushed the pharma giant higher into the close — and kept the shares firm in extended trading. After the closing bell on
16 December 2025
 ·  ·  ·  ·  ·  · 
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Dec. 12, 2025 — Bristol-Myers Squibb Company (NYSE: BMY ) is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and
12 December 2025
 ·  ·  ·  · 
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven
3 December 2025
 ·  ·  ·  ·  · 
Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb (NYSE: BMY) spent Saturday, November 29, 2025 out of the trading spotlight—U.S. markets were closed—but very much in the headlines. A cluster of fresh reports focused on three themes: a fat 5.4% dividend yield, big institutional investors quietly
30 November 2025
 ·  ·  ·  ·  · 
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Financing & balance sheet: euro notes + tender offer Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with
9 November 2025
 ·  ·  ·  ·  ·  · 
Go toTop